product guide - Square Pharmaceuticals Ltd.
... (2.5 ml of syrup) 3 to 4 times a day. In motion sickness: Adults : 25 to 50 mg 3 to 4 times a day. Children (above 9.1 kg): 12.5 to 25 mg 3 to 4 times a day (5mg/ kg/ 24 hours). In parkinsonism: Adults: 25 to 50 mg 3 to 4 times a day. Children (above 9.1 kg) : 12.5 to 25 mg 3 to 4 times a day (5mg/ ...
... (2.5 ml of syrup) 3 to 4 times a day. In motion sickness: Adults : 25 to 50 mg 3 to 4 times a day. Children (above 9.1 kg): 12.5 to 25 mg 3 to 4 times a day (5mg/ kg/ 24 hours). In parkinsonism: Adults: 25 to 50 mg 3 to 4 times a day. Children (above 9.1 kg) : 12.5 to 25 mg 3 to 4 times a day (5mg/ ...
Exelon WS-119-121-G PI highlighted EN
... As a cholinesterase inhibitor, rivastigmine may exaggerate the effects of succinylcholine-type muscle relaxants during anaesthesia. Caution is recommended when selecting anaesthetic agents. Possible dose adjustments or temporarily stopping treatment can be considered if needed. In view of its pharma ...
... As a cholinesterase inhibitor, rivastigmine may exaggerate the effects of succinylcholine-type muscle relaxants during anaesthesia. Caution is recommended when selecting anaesthetic agents. Possible dose adjustments or temporarily stopping treatment can be considered if needed. In view of its pharma ...
Cyclizine lactate - Therapeutic Goods Administration
... Studies designed to detect drowsiness did not reveal sedation in healthy adults who took a single oral therapeutic dose (50 mg) of cyclizine lactate. Sedation of short duration was reported by subjects receiving intravenous cyclizine. Patients should not drive or operate machinery until they have de ...
... Studies designed to detect drowsiness did not reveal sedation in healthy adults who took a single oral therapeutic dose (50 mg) of cyclizine lactate. Sedation of short duration was reported by subjects receiving intravenous cyclizine. Patients should not drive or operate machinery until they have de ...
Prevalence and nature of adverse drug events and the potential for
... literature review were conducted to summarise previous literature on preventable ADRs and methods to assess the preventability of ADEs. Results: Swedish physicians estimated that half of their current outpatients and inpatients experienced ADEs. The one-month prevalence of self-reported ADEs in the ...
... literature review were conducted to summarise previous literature on preventable ADRs and methods to assess the preventability of ADEs. Results: Swedish physicians estimated that half of their current outpatients and inpatients experienced ADEs. The one-month prevalence of self-reported ADEs in the ...
Effects of Caffeine in Operant Learning and Locomotor Activity
... solidified our understanding of caffeine as a stimulant. It has been cited to increase general physiological arousal as measured by increased cortisol production, heart rate and respiration (Fisone, Borgvist & Usiello, 2004). In addition to its stimulant properties, caffeine is often used as a reinf ...
... solidified our understanding of caffeine as a stimulant. It has been cited to increase general physiological arousal as measured by increased cortisol production, heart rate and respiration (Fisone, Borgvist & Usiello, 2004). In addition to its stimulant properties, caffeine is often used as a reinf ...
Medication Therapy Protocols Sample
... Doebbeling et al33 prospectively compared cefazolin and cefuroxime in a randomly assigned double-blind study of 213 patients undergoing cardiovascular surgery. Cefazolin (104 patients) was given as a 1 gm preoperative dose followed by 1 gm every 8 hours x 6 doses. Cefuroxime (109 patients) was given ...
... Doebbeling et al33 prospectively compared cefazolin and cefuroxime in a randomly assigned double-blind study of 213 patients undergoing cardiovascular surgery. Cefazolin (104 patients) was given as a 1 gm preoperative dose followed by 1 gm every 8 hours x 6 doses. Cefuroxime (109 patients) was given ...
HIGHLIGHTS OF PRESCRIBING INFORMATION FULL
... • Subsequent acts of intercourse should be protected by a reliable barrier method until next menstrual period. If a woman wishes to use hormonal contraception, she should do so no sooner than 5 days after intake of ella. (5.5) • Ectopic pregnancy: Women who become pregnant or complain of lower abd ...
... • Subsequent acts of intercourse should be protected by a reliable barrier method until next menstrual period. If a woman wishes to use hormonal contraception, she should do so no sooner than 5 days after intake of ella. (5.5) • Ectopic pregnancy: Women who become pregnant or complain of lower abd ...
(MMP)-2 and - UTHSC Digital Commons
... sympathetic activity in the central nervous system, reducing saliva secretion by stimulation of inhibitory α2 receptors resulting in reductions in unstimulated salivary flow. What little saliva is produced is high in protein, thereby increasing the patient’s sensation of oral dryness.18 METH abusers ...
... sympathetic activity in the central nervous system, reducing saliva secretion by stimulation of inhibitory α2 receptors resulting in reductions in unstimulated salivary flow. What little saliva is produced is high in protein, thereby increasing the patient’s sensation of oral dryness.18 METH abusers ...
Full-Text PDF
... clinic involves careful assessment of their safety profiles, which, among other end-points, includes the clinic involves careful assessment of their safety profiles, which, among other end-points, includes evaluation of immunotoxicity [68]. Moreover, since physico-chemical properties of nanoparticle ...
... clinic involves careful assessment of their safety profiles, which, among other end-points, includes the clinic involves careful assessment of their safety profiles, which, among other end-points, includes evaluation of immunotoxicity [68]. Moreover, since physico-chemical properties of nanoparticle ...
ABCB1 haplotypes do not influence transport Linköping University Post Print
... as well as imatinib plasma concentration have previously been correlated with the outcome of CML therapy. 13–15 These findings indicate that analysis of drug-transport activity, or markers thereof, might be useful predictors of response to imatinib, and perhaps to the second-generation TKIs as well. ...
... as well as imatinib plasma concentration have previously been correlated with the outcome of CML therapy. 13–15 These findings indicate that analysis of drug-transport activity, or markers thereof, might be useful predictors of response to imatinib, and perhaps to the second-generation TKIs as well. ...
Report of the National Lipid Association`s Statin Safety Task Force
... John R. Guyton, MD, is a member of the Speakers’ Bureau for Abbott Laboratories, AstraZeneca, Kos Pharmaceuticals, Merck & Co., Pfizer Inc., Schering-Plough, and Takeda Pharmaceuticals America; serves as a consultant to Merck/Schering-Plough, Oryx Pharmaceuticals, Sankyo Pharma, and Takeda Pharmaceu ...
... John R. Guyton, MD, is a member of the Speakers’ Bureau for Abbott Laboratories, AstraZeneca, Kos Pharmaceuticals, Merck & Co., Pfizer Inc., Schering-Plough, and Takeda Pharmaceuticals America; serves as a consultant to Merck/Schering-Plough, Oryx Pharmaceuticals, Sankyo Pharma, and Takeda Pharmaceu ...
PRODUCT INFORMATION METHADONE SYRUP
... Adults: Usual single dose 5-10 mg by mouth. Owing to its long plasma half-life, caution with repeated dosage should be observed in all patients, particularly in the very ill or elderly. The usual initial dose should be 5-10 mg 6-8 hourly, later adjusted to the degree of pain relief obtained. Doses a ...
... Adults: Usual single dose 5-10 mg by mouth. Owing to its long plasma half-life, caution with repeated dosage should be observed in all patients, particularly in the very ill or elderly. The usual initial dose should be 5-10 mg 6-8 hourly, later adjusted to the degree of pain relief obtained. Doses a ...
ZITHROMAX®
... regimen of 500 mg on Day 1 and 250 mg/day on Days 2-5, Cmin and Cmax remained essentially unchanged from Day 2 through Day 5 of therapy. However, without a loading dose, azithromycin Cmin levels required 5 to 7 days to ...
... regimen of 500 mg on Day 1 and 250 mg/day on Days 2-5, Cmin and Cmax remained essentially unchanged from Day 2 through Day 5 of therapy. However, without a loading dose, azithromycin Cmin levels required 5 to 7 days to ...
pharmacological manipulation of cb1 receptor
... et al., 1999; Freedland et al., 2001; Lallemand et al., 2001). In addition, SR141716A has been shown to have a relatively flat dose–response curve, with 1 and 3 mg/kg having effects on EtOH and sucrose consumption, while higher doses result in competing behaviours such as excessive scratching and gr ...
... et al., 1999; Freedland et al., 2001; Lallemand et al., 2001). In addition, SR141716A has been shown to have a relatively flat dose–response curve, with 1 and 3 mg/kg having effects on EtOH and sucrose consumption, while higher doses result in competing behaviours such as excessive scratching and gr ...
as a PDF
... Abstract — Aims: The current study investigated the efficacy of CB1 receptor-targeted drugs on the development and expression of tolerance to alcohol (EtOH). Methods: An EtOH-inhalation model was used to induce tolerance, as measured by EtOH-induced sedation and hypothermia after a 24 h withdrawal p ...
... Abstract — Aims: The current study investigated the efficacy of CB1 receptor-targeted drugs on the development and expression of tolerance to alcohol (EtOH). Methods: An EtOH-inhalation model was used to induce tolerance, as measured by EtOH-induced sedation and hypothermia after a 24 h withdrawal p ...
Comparison of Anti-Xa and Dilute Russell Viper Venom Time
... method for determining rivaroxaban levels (Figure 2, C). COMMENT Although routine laboratory monitoring is not required when patients are administered rivaroxaban, there are several clinical situations where determination of the level of anticoagulation is of value. There have been recent reports ev ...
... method for determining rivaroxaban levels (Figure 2, C). COMMENT Although routine laboratory monitoring is not required when patients are administered rivaroxaban, there are several clinical situations where determination of the level of anticoagulation is of value. There have been recent reports ev ...
Guideline for the Quality, Safety, and Efficacy Assurance of Follow
... For the development of a follow-on biologic, the manufacturing process should be established independently of that of the original biologic, and the quality attributes of the follow-on biologic should be thoroughly characterized, as in the case of new recombinant protein products. In addition, a hi ...
... For the development of a follow-on biologic, the manufacturing process should be established independently of that of the original biologic, and the quality attributes of the follow-on biologic should be thoroughly characterized, as in the case of new recombinant protein products. In addition, a hi ...
maxzide
... MAXZIDE may be used alone or in combination with other antihypertensive drugs, such as betablockers. Since MAXZIDE (triamterene and hydrochlorothiazide) may enhance the actions of these drugs, dosage adjustments may be necessary. Us age in Pregnancy The routine use of diuretics in an otherwise healt ...
... MAXZIDE may be used alone or in combination with other antihypertensive drugs, such as betablockers. Since MAXZIDE (triamterene and hydrochlorothiazide) may enhance the actions of these drugs, dosage adjustments may be necessary. Us age in Pregnancy The routine use of diuretics in an otherwise healt ...
The Eclectic Materia Medica, Pharmacology and Therapeutics by
... unimpaired until just before death, showing that aconite probably does not greatly impress the cerebrum. The one diagnostic symptom of aconite poisoning is the characteristic aconite tingling. If confession (in case of attempted suicide) is not forthcoming or the patient is unable to reveal the fact ...
... unimpaired until just before death, showing that aconite probably does not greatly impress the cerebrum. The one diagnostic symptom of aconite poisoning is the characteristic aconite tingling. If confession (in case of attempted suicide) is not forthcoming or the patient is unable to reveal the fact ...
Lamictal XR (lamotrigine) Extended-Release Tablets
... (1) Taking Estrogen-Containing Oral Contraceptives: In women not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7), Cli ...
... (1) Taking Estrogen-Containing Oral Contraceptives: In women not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7), Cli ...
UK/H/1304/001-003/DC - Medicines and Healthcare products
... Oxcarbazepine and its pharmacologically active metabolite (the monohydroxy derivative, MHD) are weak inducers in vitro and in vivo of the cytochrome P450 enzymes CYP3A4 and CYP3A5 responsible for the metabolism of a very large number of substances, for example, immunosuppressants (e.g. ciclosporin, ...
... Oxcarbazepine and its pharmacologically active metabolite (the monohydroxy derivative, MHD) are weak inducers in vitro and in vivo of the cytochrome P450 enzymes CYP3A4 and CYP3A5 responsible for the metabolism of a very large number of substances, for example, immunosuppressants (e.g. ciclosporin, ...
How close are you to your blood pressure and
... CADUET® (amlodipine besylate/atorvastatin calcium) tablets are not for everyone, including anyone who has previously had an allergic reaction to CADUET or to any of the inactive ingredients. It is not for those with liver problems. And it is not for women who are nursing, pregnant, or may become pre ...
... CADUET® (amlodipine besylate/atorvastatin calcium) tablets are not for everyone, including anyone who has previously had an allergic reaction to CADUET or to any of the inactive ingredients. It is not for those with liver problems. And it is not for women who are nursing, pregnant, or may become pre ...
Journal home page: http://www.iajpr.com/index.php/en/ INDO
... Tremendous approved pharmacological activity of Aegle marmelos Antidiabetic activity Diabetes mellitus is metabolic disorder which independent risk factor for coronary artery disease, hypertension, myocardial infaraction & hyperlipidemia. Diabetes & its related complication are closely related with ...
... Tremendous approved pharmacological activity of Aegle marmelos Antidiabetic activity Diabetes mellitus is metabolic disorder which independent risk factor for coronary artery disease, hypertension, myocardial infaraction & hyperlipidemia. Diabetes & its related complication are closely related with ...
Pilocarpine-Induced Convulsive Activity Is Limited by Multidrug
... SE Induction by Pilocarpine in Mice. In total, 53 (21 males, 32 females) WT mice and 65 (25 males, 40 females) Mdr1a/b(2/2) mice were used for SE induction experiments. To reduce peripheral side effects of pilocarpine, mice were pretreated with 1 mg×kg21 i.p. methylscopolamine 30 minutes before the ...
... SE Induction by Pilocarpine in Mice. In total, 53 (21 males, 32 females) WT mice and 65 (25 males, 40 females) Mdr1a/b(2/2) mice were used for SE induction experiments. To reduce peripheral side effects of pilocarpine, mice were pretreated with 1 mg×kg21 i.p. methylscopolamine 30 minutes before the ...
November 2015 PBAC Meeting Agenda
... circumstances, consumers will be able to comment on items in other sections of the agenda. The submissions for which input is sought will be listed in alphabetical order by drug name. There is no provision for consumer comments to the PBAC on agenda item 8 which relates to pricing matters. Pharmaceu ...
... circumstances, consumers will be able to comment on items in other sections of the agenda. The submissions for which input is sought will be listed in alphabetical order by drug name. There is no provision for consumer comments to the PBAC on agenda item 8 which relates to pricing matters. Pharmaceu ...